US20100305081A1 - Organo-gel formulations for therapeutic applications - Google Patents

Organo-gel formulations for therapeutic applications Download PDF

Info

Publication number
US20100305081A1
US20100305081A1 US12/856,292 US85629210A US2010305081A1 US 20100305081 A1 US20100305081 A1 US 20100305081A1 US 85629210 A US85629210 A US 85629210A US 2010305081 A1 US2010305081 A1 US 2010305081A1
Authority
US
United States
Prior art keywords
composition
weight
agent
urea
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/856,292
Inventor
Frederick J. Dechow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MediQuest Therapeutics Inc
Original Assignee
MediQuest Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/960,516 external-priority patent/US7740875B2/en
Application filed by MediQuest Therapeutics Inc filed Critical MediQuest Therapeutics Inc
Priority to US12/856,292 priority Critical patent/US20100305081A1/en
Publication of US20100305081A1 publication Critical patent/US20100305081A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015Drug-containing film-forming compositions, e.g. spray-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/042Gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/345Alcohols containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42Amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • A61K8/553Phospholipids, e.g. lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • This disclosure relates to a composition useful in the local delivery of cosmetic and/or pharmaceutical agents into the skin and nails.
  • This composition allows the formulation with the agent(s) to be rapidly absorbed through the skin, to pass through nails, and also to have a pleasing, non-greasy, non-oily appearance and feel.
  • the skin is the largest organ in the body and serves important functions that are necessary to life.
  • the skin acts as a barrier to the invasion of various pathogens and toxic substances.
  • Skin is composed of the two layers: the epidermis is the first layer; and the dermis is the layer below the epidermis.
  • the skin is highly impermeable. It must be impermeable to preserve its own integrity while at the same time maintaining the delicate dynamic electrolyte balance of the body.
  • the skin must serve a containment function; it must also function as a microbial, chemical, radiation and thermal barrier.
  • the horny cutaneous plates on the dorsal surface of the distal end of the terminal phalanx of a finger or toe (fingernails and toenails). They are made up of flattened epithelial scales developed from specialized epithelial cells called the matrix. The thick and hardened nature of nails renders access through, and to the area below, nearly impossible with current topical formulations.
  • the subject of the present disclosure has the advantage of being able to delivery pharmaceutical agents through the unguis to heretofore minimally accessible disease targets.
  • the art has turned to the use of specifically selected vehicles and carriers into which the pharmaceutical active is incorporated so that the vehicle or carrier aids in, or at a minimum does not adversely affect, the penetration of the selected active agent.
  • the art recognizes that to a vast degree the rate of percutaneous delivery of a pharmaceutical active can be significantly decreased by the selection of an improper vehicle.
  • the advantages of this form of delivery include, but are not limited to: avoidance of the risks associated with parenteral treatment; elimination of the inconveniences of parenteral treatment; avoidance of the variable rates of absorption and metabolism inherent in oral treatment; increasing the continuity of drug administration by permitting delivery of agents with short biological half-lives; and elimination of gastrointestinal irritation resulting from exposing the gastrointestinal tract to pharmaceutical actives, preservatives, tableting agents, and the like.
  • topical delivery possesses the potential for effectively treating conditions which are local in nature (or which exhibit local manifestations), systemically as well as locally with the same treatment regimen.
  • effective compositions to deliver pharmaceutical agents are highly sought after.
  • compositions have been suggested for the precutaneous delivery of certain pharmaceutically active agents, a need exists for achieving enhanced delivery of cosmetic and pharmaceutical agents to the skin for local treatment of skin conditions and diseases.
  • the composition should be easy to apply topically in a quantitative amount, to allow the active agent to rapidly permeate the skin to get where the agent is needed, to have a pleasant odor and appearance, and to not require cleansing to remove the agent.
  • the present disclosure relates to a composition for the local delivery of at least one cosmetic or pharmaceutical agent or both.
  • the composition comprises at least two biocompatible organic solvents, a polar lipid, at least one surfactant, water, urea and a thickener.
  • the organic solvents comprise an ester and a dihydric and/or polyhydric alcohol.
  • the composition comprises about 2 to about 30% by weight of the ester and about 0.5 to about 20% by weight of the dihydric and/or polyhydric alcohol.
  • the present disclosure also relates to a method of delivering an active agent into and through the epidermis or ungual tissue of a human or animal comprising topically applying to the skin or to the nail of the human or animal a composition comprising a cosmetic and/or pharmaceutically active agent and the composition disclosed above.
  • compositions comprising the above disclosed delivery composition and a cosmetic and/or pharmaceutically active agent.
  • the pH of the composition containing the active agent is typically about 5.5 to about 7.5.
  • a still further aspect of the present invention relates to a method for making a composition suitable for the cutaneous delivery of a cosmetic and/or pharmaceutically active agent which comprises:
  • the present disclosure further relates to a composition prepared by the above disclosed method.
  • topical administration is meant directly laying or spreading upon epidermal or ungual tissue, especially outer skin, nails, or membrane, including the skin or membrane of the oral, rectal, or vaginal cavities.
  • safety and effective amount is meant a sufficient amount of the composition to provide the desired local therapeutic activity and performance at a reasonable benefit/risk ratio attendant any medical treatment.
  • amount of active agent used will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the specific active ingredient(s) employed, its or their concentration, the condition of the patient, concurrent therapies being administered, and like factors within the specific knowledge and expertise of the patient or the attending physician.
  • ERTAINly- or pharmacologically-acceptable is meant the pharmaceutical actives, as well as other compatible drugs, medicaments or inert ingredients which the term describes are suitable for use in contact with the tissues of human and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
  • compositions and methods of this invention are meant that various other compatible cosmetics, drugs and medicaments, as well as inert ingredients, occlusive agents, and cosmetic vehicles, can be conjointly employed in the compositions and methods of this invention, as long as the critical binary penetration enhancement vehicle and cosmetic or pharmaceutical active are used.
  • the term “comprising” thus encompasses and includes the more restrictive terms “consisting of” and “consisting essentially of” which characterize the use of the essential ingredients in the manner disclosed herein.
  • afflicted sites is meant a localized area of pathology, discomfort, infection, inflammation or lesion, and the immediately surrounding area.
  • application sites is meant a site suitable for application via a mechanical sustained release device or dressing, e.g., behind the ear, on the arm, back, top of the foot, etc.
  • penetration-enhancing is meant that the binary penetration enhancing carriers of this disclosure provide marked transepidermal, transungual or percutaneous delivery of an incorporated active, when compared to other compositions at equal chemical potential.
  • This latter aspect is important, since varying solubilities of cosmetics or drugs in different vehicles will necessarily affect their transport across skin or through nails.
  • the lower solubility carrier will show a misleading six-fold difference in transport over the more soluble vehicle.
  • the simplest way of assuring equal chemical potential for evaluating penetration enhancement is to use saturated solutions or solutions of equal percentage of saturation of pharmacological active in the various vehicles.
  • compositions of this disclosure contain a cosmetic agent and/or pharmaceutically-active agent capable of producing or possessing local activity, in a binary vehicle or carrier.
  • vehicle on carrier comprises a polar lipid, such as lecithin or phosphotidylcholine, and two biocompatible organic solvents, one chosen from the group of esters and one chosen from the group of liquid dihydric and polyhydric alcohols, a preservative, water, a thickener and urea, at a pH of between about 5.5 and 7.5 and preferably between 6.0 and 7.0.
  • the compositions of this disclosure may additionally contain other optional components that reduce skin irritation, or enhance their cosmetic appeal or acceptability, e.g, pigments, fragrances, perfumes, and the like.
  • Typical polar lipids employed are lecithin and phosphotidylcholine.
  • the lecithin or phosphatidylcholine is of a high quality, pharmaceutical grade.
  • Appropriate lecithin and phosphatidylcholine maybe obtained as commercially available soya lecithin or soya phosphatidylcholine.
  • soya lecithin is used in the composition of this invention.
  • the biocompatible organic ester solvents may be any non-toxic ester in which the polar lipid, the cosmetic or pharmaceutically active compound and urea are soluble, and which assists as a solubilizing vehicle for carrying cosmetic or pharmaceutically active compounds across the skin of a mammal.
  • the esters are fatty mono esters having a structure, obtainable by replacing the active hydrogen of a fatty acid having 4 to 22 carbon atoms and more typically having 8 to 18 carbon atoms by the alkyl group of a monohydric alcohol, particular example being 12 carbon atoms.
  • the fatty acid can be saturated or unsaturated and more typically is saturated.
  • the monohydric alcohol typically contains 2 to 8 carbon atoms and more typically 2 to 5 carbon atoms, a particular example being 3 carbon atoms.
  • Acceptable esters for this purpose include, but are not limited to isopropyl esters.
  • the ester is isopropyl myristate or isopropyl palmitate, with isopropyl myristate being particularly preferred.
  • the biocompatible organic dihydric and polyhydric alcohol solvents may be any non-toxic di or polyalcohol in which the polar lipid and the active compound are soluble, and which assists as a solubilizing vehicle for carrying active compounds across the skin of a mammal.
  • Acceptable dihydric and polyalcohols for this purpose include, but are not limited to di- and tri-alcohol alkanes.
  • the alcohols contain 3 to 8 carbon atoms and more typically 3 to 5 carbon atoms and are saturated alcohols.
  • the polyalcohol is propylene glycol or glycerol, with propylene glycol being particularly preferred.
  • compositions of the present disclosure typically contain about 2 to 30% by weight and more typically 4 to 10% by weight of the ester and about 0.5 to about 20% by weight, more typically 1 to about 20% weight, and even more typically 1 to about 10% weight of the alcohol. Many of the compositions contain about 2 to about 20% by weight or, 2 to about 10% weight of the alcohol. Compositions according to the present disclosure exhibit reduced skin irritation.
  • the polar lipid is typically dissolved in the organic ester solvent and di or polyalcohol solvent at mass ratios from about 5:1:1 to about 1:5:5.
  • the polar lipid and organic ester solvent and polyalcohol solvent are mixed in equal mass ratios.
  • soya lecithin, isopropyl myristate, and propylene glycol are mixed in equal mass ratios and mixed until the lecithin is evenly distributed. This is referred to as the solvent-polar lipid mixture.
  • a surfactant can be included in the formulation at a concentration of between about 1-20% of the final composition mass.
  • a surfactant is one which is compatible with administration in vivo without elicitation of undesirable side effects.
  • One preferred surfactant is docusate sodium and its more water soluble form, docusate sodium benzoate.
  • ionic or non-ionic surfactants such as polysorbate 80, Tween 80, docusate calcium, tetradecyltrimethylammonium bromide, pentaoxyetylene glycol monododecyl ether, or triethanolamine laureth sulfate. Once the surfactant is thoroughly dispersed in the solvent-polar lipid mixture, the cosmetic or pharmaceutically active compound may be added and dissolved.
  • the dosage of the cosmetic or pharmaceutical agent will, of course, vary depending upon known factors, such as the cosmetic or pharmaceutical agent characteristics of the particular agent; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired.
  • a daily dosage of active ingredient can be expected to be about 0.001 to 1000 milligrams (mg) per kilogram (kg) of body weight, with the more typical dose being 0.1 to about 30 mg/kg.
  • the active agent is typically present in amounts of about 0.001 to about 30%, more typically about 0.001 to about 20%, and even more typically about 0.5 to 12% by weight based upon the total of the delivery system and active agent. For solid active ingredients, this is most easily achieved by heating an aliquot of the surfactant-solvent-polar lipid mixture and adding, on a mass basis, an amount of active compound equal to about 0.01 to 30% of the mass of the surfactant-solvent-polar lipid and mixing until completely dissolved.
  • about 1-20 grams of nifedipine in a powdered form is added to about 100 grams of heated 1:0.5:0.5 soya lecithin:isopropyl myristate:propylene glycol and allowed to dissolve with stirring.
  • Some exemplary active agents include vasodilating agents such as glyceryl trinitrate and nifedipine; antimicrobial or antifungal agents such as ciclopirox, itraconazole, metronidazole, miconazole and allylamines such as, naftifine and terbinafine and salts thereof; inhibitors of cell growth or proliferation, such as 2-deoxy-D-glucose; inhibitors of polyamine transport; inhibitors of polyamine synthesis; antizyme inducers; decalcifying skin agents such as lactic acid; anti-inflammatory agents such as ibuprofen and ketoprofen; topical anaesthetics such as lidocaine; steroidal anti-inflammatory compounds, such as cortisone; peptides, proteins, or hormones, such as platelet factor 4; substance P antagonists such as capsaicin; muscle relaxants such as cyclobenzaprine; anti-inflammatory analgesics such as diclofenac sodium and phosphodieste
  • the active in the case of the active nitroglycerin, is available in the form of a 10% concentration in propylene glycol, which can be added directly to the polar lipid-solvent-surfactant mixture.
  • the amount of a vasodilator for the treatment of peripheral arterial diseases is typically about 0.2 to about 1.8% of the composition.
  • the amount of antimicrobial agent or antifungal agent for the treatment of infectious diseases of the skin and nails, including onychomycosis, athlete's foot, rosacea, and vaginomycosis is typically about 0.5 to about 12% by weight.
  • the amount of an inhibitor of cell growth or proliferation for treatment of actinic keratosis is about 0.001 to about 10% of weight.
  • the amount of an inhibitor of polyamine transport is typically about 0.001 to about 5% by weight.
  • the amount of an inhibitor of polyamine synthesis for the treatment of an automimmune disease, including cutaneous lupus erythrematosus, urticaria, psoriasis, and atopic dermatosis is typically about 0.001 to about 5% by weight.
  • the amount of a decalcifying skin agent, such as lactic acid, for the treatment of dry skin conditions, including xerosis, scleroderma, and ichthyosis is typically about 0.5 to about 10% by weight.
  • two or more different types of active agents can be employed in order to treat more than one condition at the same time.
  • two or more active agents can be used to treat inflammatory, autoimmune, infectious and/or dry skin conditions simultaneously.
  • an amount of urea preferably as a thickened aqueous solution, can be added to the surfactant-solvent-polar lipid mixture.
  • the urea is typically added so that the urea concentration about 1% to about 15% and more typically about 5% and 10% by mass of the final composition mass.
  • the thickener is selected from common National Formulary thickening agents including, but not limited to appropriate polymer weights of polyethylene glycol, polyvinylpyrrolidone, carbomer and methylcellulose.
  • the amount of thickener is typically about 0.05 to about 5% by weight.
  • a 10% aqueous solution of urea containing 0.7% Carbomer 934
  • the pharmaceutically active agent will more readily dissolve if added after addition of the aqueous urea solution, and in other instances before the addition of aqueous urea solution. In any event, this is a choice readily made by those skilled in the art, once aware of the present disclosure, depending on the particular formulation being prepared and the solubility characteristics of the particular cosmetic or pharmaceutically active compound being solubilized.
  • the active agent is a protein
  • the pH is adjusted to typical pH of about 5.5 to about 7.5 and more typically to a 6.0 to 7.0.
  • a base such as aqueous sodium hydroxide and trolamine
  • an acid to reduce the pH would be desirable.
  • an acid such as citric acid or a biological buffer such as sodium carbonate or potassium phosphate.
  • the composition is formulated with a vasodilating agent, such as glyceryl trinitrate.
  • a vasodilating agent such as glyceryl trinitrate.
  • Such formulation is rapidly absorbed through the skin and provides local vasodilation, increases in blood flow, and restoration of normal temperature to an extremity with low blood flow.
  • the composition is formulated with an anti-infective agent. Such formulation is rapidly absorbed through the skin, or somewhat more slowly through the nails to provide local delivery to kill invading microorganisms such as fungi or bacteria.
  • compositions can contain auxiliary agents including those conventionally known and/or used in this art such as, but not limited to, preservatives and fragrances.
  • MQX-GEL a first gel composition
  • a MQX-GEL may be prepared by mixing lecithin organogel (L.O.), as a 1:1:1 (m/m/m) mixture of lecithin, isopropyl myristate and propylene glycol, with LID oil (a 1:1 [m/m] mixture of L.O. and docusate sodium), dissolving additional surfactant and/or docusate sodium powder into this mixture, and then adding thickened aqueous urea.
  • L.O. lecithin organogel
  • LID oil a 1:1 [m/m] mixture of L.O. and docusate sodium
  • the solubilized active ingredients may then be added to MQX-GEL.
  • Excipients which may be useful in solubilizing the active ingredient include L.O., propylene glycol, isopropyl myristate, peppermint oil, glycerin, and/or polyethylene glycol. A homogenous mixture is then made by carefully blending the various components.
  • formulations described above have been prepared, use of the formulations is a simple matter of applying the formulation to affected areas where cutaneous delivery of the pharmaceutically active agent is desired.
  • formulations containing glyceryl trinitrate are rubbed over the affected area such as the fingers of the hands. Treatment is repeated as symptoms reappear or when used as a prophylactic treatment, just before symptoms may appear.
  • normal blood flow in the fingers of the Raynaud's patient has been restored within five minutes of application.
  • an anti-fungal anti-microbial compound is formulated for delivery to toe nails infected with fungus.
  • doctors and patients across the country have confirmed almost complete reduction in fungal infection. This is in contrast to results observed with current commercial topical formulations with this same active ingredient that provide very modest reduction in fungal infection in the same time frame.
  • a still further indication for the organogel compositions of this disclosure is for treating nail psoriasis.
  • active ingredients to use include one or more of the compounds useful in the treatment of psoriasis, typically in amounts of about 0.0005% to 10% depending upon the type of agent, such as, corticosteroids (Clobetasol propionate about 0.005-about 0.05%, Betamethasone dipropionate about 0.005-about 0.05%, Diflorasone diacetate about 0.005-about 0.05%, Halcinonide about 0.01-about 0.1%, Desoximetasone about 0.005-about 0.5%, Triamcinolone acetonide about 0.01-about 0.5%), anti-proliferative cancer agents (flourouracil, methotrexate, polyamine synthesis and transport inhibitors, antizyme inducers, each about 0.05-about 5.0%), retinoids (tazarotene, acetretin), vitamin D analogs (calcipot
  • compositions comprising an antibacterial agent are prepared, for example, by inclusion of bacitracin or another appropriate antibiotic. This allows for penetration of the antibacterial agent to sites of infection induced by puncture wounds.
  • compositions of this invention are provided at a concentration of between about 0.001% to 30% by weight of active compound.
  • compositions comprising more than one active ingredient are within the scope of this disclosure and could be administered to a recipient in need of more than a single active treatment at one localized spot.
  • a composition comprising a vasodilating agent and an antifungal would both provide relief from fungal infection and will facilitate long-term relief by restoring blood flow and the flow of nutrients to the affected area.
  • compositions of this disclosure are applied topically as frequently as required as long as local reactions or toxicity due to the active ingredient do not become a problem.
  • a more rigorously monitored regimen of application may be required when an anti-neoplastic compound is being administered than when a readily metabolized non-toxic compound such as ketoprofen is administered.
  • the LID was added to L.O. and heated.
  • MQX-GEL may just as easily be prepared as follows:
  • the L.O. was heated and the docusate sodium benzoate powder was stirred into the heated L.O. until a smooth solution is prepared.
  • the water was heated and the thickener and urea were dissolved into the water, and the thickened urea solution was then thoroughly mixed with the docusate sodium containing solution of L.O.
  • the result was a consistent, transparent, amber colored gel with a pH of about 6.0.
  • a further method of making MQX-GEL is as follows:
  • the LID and L.O. were mixed well and a heated solution of water, the thickener and the urea was prepared and added to the LID-L.O. solution.
  • the result was a consistent, transparent, amber colored gel with a pH of about 6.0.
  • Carbomer 934 and Methylcellulose are added to thicken the urea-water of step 3.
  • the lecithin organogel with the active component from step 2 is combined with the thickened aqueous urea from step 4 to form a uniform mixture.
  • MQX-GEL can also be prepared with other ratios of the three constituents of the lecithin organogel.
  • the ratio of lecithin organogel (L.O.#2), is a 1:0.9:0.1 (m/m/m) mixture of lecithin, isopropyl myristate and propylene glycol, with LID oil (a 1:1 [m/m] mixture of L.O.#2 and docusate sodium), dissolving additional surfactant and/or docusate sodium powder into this mixture, and then adding thickened aqueous urea.
  • the solubilized active ingredients may then be added to MQX-GEL.
  • Excipients which may be useful in solubilizing the active ingredient include L.O.#2, propylene glycol, isopropyl myristate, peppermint oil, glycerin, and/or polyethylene glycol. A homogenous mixture is then made by carefully blending the various components.
  • Carbomer 934 and Methylcellulose are added to thicken the urea-water of step 3.
  • the lecithin organogel with the active from step 2 is combined with the thickened aqueous urea from step 4 to form a uniform mixture.
  • Urea is added to distilled water, with heating and stirring to obtain a uniform solution.
  • Carbomer 934 and Methylcellulose are added to thicken the urea-water of step 3.
  • the lecithin organogel with the actives from step 2 is combined with the thickened aqueous urea from step 4 to form a uniform mixture.
  • Carbomer 934 and Methylcellulose are added to thicken the urea-water of step 3.
  • the lecithin organogel with the actives from step 2 is combined with the thickened aqueous urea from step 4 to form a uniform mixture.
  • the pH is adjusted to 6.5 with dilute aqueous NaOH to form an elegant thick gel.
  • Carbomer 934 and Methylcellulose are added to thicken the urea-water of step 3.
  • the lecithin organogel with the active from step 2 is combined with the thickened aqueous urea from step 4 to form a uniform mixture.
  • a formulation is prepared along the lines of Example 6 containing 2% miconazole nitrate, 48.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • a formulation is prepared along the lines of Example 6 containing 2% naftifine hydrochloride, 48.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • a formulation is prepared along the lines of Example 6 containing 5% terbinafine hydrochloride, 45.5% distilled water, 9.75% urea, 0.7% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • a formulation is prepared along the lines of Example 6 containing 2% ciclopirox olamine, 48.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • a formulation is prepared along the lines of Example 6 containing 4% ciclopirox olamine, 46.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • a formulation along the lines of example 11 can be prepared by replacing the 2% miconazole with 0.001% betamethasone dipropionate and 2.5% methotrexate.
  • a formulation along the lines of example 11 can be prepared by replacing the 2% miconazole with 0.001% betamethasone dipropionate, 2.5% methotrexate, and 2% miconazole.

Abstract

A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided. Also disclosed are compositions that further contain a cosmetic and/or pharmaceutical agent, along with the preparation and use thereof

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of co-pending U.S. application Ser. No. 11/246,296, filed Oct. 11, 2005, entitled ORGANO-GEL FORMULATIONS FOR THERAPEUTIC APPLICATIONS, which in turn is a continuation-in-part of my copending U.S. application Ser. No. 11/150,254, filed Jun. 13, 2005, entitled ORGANO-GEL FORMULATIONS FOR THERAPEUTIC APPLICATIONS, which in turn is a continuation-in part of my copending U.S. application Ser. No. 11/066,485, filed Feb. 28, 2005, entitled ORGANO-GEL FORMULATIONS FOR THERAPEUTIC APPLICATIONS, which in turn is a continuation-in-part of my copending U.S. application Ser. No. 10/960,516, filed Oct. 8, 2004, entitled ORGANO-GEL FORMULATIONS FOR THERAPEUTIC APPLICATIONS, entire disclosures of which are being incorporated herein by reference.
  • TECHNICAL FIELD
  • This disclosure relates to a composition useful in the local delivery of cosmetic and/or pharmaceutical agents into the skin and nails. This composition allows the formulation with the agent(s) to be rapidly absorbed through the skin, to pass through nails, and also to have a pleasing, non-greasy, non-oily appearance and feel.
  • BACKGROUND
  • The skin is the largest organ in the body and serves important functions that are necessary to life. The skin acts as a barrier to the invasion of various pathogens and toxic substances. Skin is composed of the two layers: the epidermis is the first layer; and the dermis is the layer below the epidermis.
  • However, because it must serve as a barrier to the ingress of pathogens and toxic materials, and the egress of physiologic fluids, the skin is highly impermeable. It must be impermeable to preserve its own integrity while at the same time maintaining the delicate dynamic electrolyte balance of the body. The skin must serve a containment function; it must also function as a microbial, chemical, radiation and thermal barrier.
  • A good deal of this impermeability of the skin results from the nature of one very thin layer created by normal developmental and physiological changes in the skin. After cells are formed in the basal layer, they begin to migrate toward the skin surface, until they are eventually sloughed off. As they undergo this migration, they become progressively more dehydrated and keratinized. When they reach the surface, just prior to being discarded, they form a thin layer of dense, metabolically inactive cells approximately ten microns (10-15 cells) thick. This layer is called the stratum corneum or the “cornified layer”. As a result of the high degree of keratinization of the cells which comprise the stratum corneum, a formidable barrier is created. Therefore, penetration via the nonpolar route, i.e., across the membrane of these cells, remains most difficult.
  • The problem is even more difficult when trying to deliver pharmaceutical agents through the unguis, the horny cutaneous plates on the dorsal surface of the distal end of the terminal phalanx of a finger or toe (fingernails and toenails). They are made up of flattened epithelial scales developed from specialized epithelial cells called the matrix. The thick and hardened nature of nails renders access through, and to the area below, nearly impossible with current topical formulations. The subject of the present disclosure has the advantage of being able to delivery pharmaceutical agents through the unguis to heretofore minimally accessible disease targets.
  • Accordingly, in an effort to take advantage of this route of administration and overcome the obstacles the skin and nails naturally provide, the art has turned to the use of specifically selected vehicles and carriers into which the pharmaceutical active is incorporated so that the vehicle or carrier aids in, or at a minimum does not adversely affect, the penetration of the selected active agent. The art recognizes that to a vast degree the rate of percutaneous delivery of a pharmaceutical active can be significantly decreased by the selection of an improper vehicle.
  • Because of the ease of access, dynamics of application, large surface area, vast exposure to the circulatory and lymphatic networks, and non-invasive nature of the treatment, the delivery of pharmaceutically-active agents through the skin has long been a promising concept. This is true whether the bioavailability desired is systemic or dermal, regional or local.
  • The advantages of this form of delivery include, but are not limited to: avoidance of the risks associated with parenteral treatment; elimination of the inconveniences of parenteral treatment; avoidance of the variable rates of absorption and metabolism inherent in oral treatment; increasing the continuity of drug administration by permitting delivery of agents with short biological half-lives; and elimination of gastrointestinal irritation resulting from exposing the gastrointestinal tract to pharmaceutical actives, preservatives, tableting agents, and the like. Most importantly, topical delivery possesses the potential for effectively treating conditions which are local in nature (or which exhibit local manifestations), systemically as well as locally with the same treatment regimen. Thus, effective compositions to deliver pharmaceutical agents are highly sought after.
  • Although various compositions have been suggested for the precutaneous delivery of certain pharmaceutically active agents, a need exists for achieving enhanced delivery of cosmetic and pharmaceutical agents to the skin for local treatment of skin conditions and diseases. In particular, the composition should be easy to apply topically in a quantitative amount, to allow the active agent to rapidly permeate the skin to get where the agent is needed, to have a pleasant odor and appearance, and to not require cleansing to remove the agent.
  • This combination of these desired characteristics is difficult to achieve.
  • SUMMARY
  • The present disclosure relates to a composition for the local delivery of at least one cosmetic or pharmaceutical agent or both. The composition comprises at least two biocompatible organic solvents, a polar lipid, at least one surfactant, water, urea and a thickener. The organic solvents comprise an ester and a dihydric and/or polyhydric alcohol. The composition comprises about 2 to about 30% by weight of the ester and about 0.5 to about 20% by weight of the dihydric and/or polyhydric alcohol.
  • The present disclosure also relates to a method of delivering an active agent into and through the epidermis or ungual tissue of a human or animal comprising topically applying to the skin or to the nail of the human or animal a composition comprising a cosmetic and/or pharmaceutically active agent and the composition disclosed above.
  • Another aspect of the present disclosure relates to a composition comprising the above disclosed delivery composition and a cosmetic and/or pharmaceutically active agent. The pH of the composition containing the active agent is typically about 5.5 to about 7.5.
  • A still further aspect of the present invention relates to a method for making a composition suitable for the cutaneous delivery of a cosmetic and/or pharmaceutically active agent which comprises:
      • a. Dissolving a polar lipid at least in two biocompatible organic solvents comprising at least one ester and at lease one dihydric or polyhydric alcohol;
      • b. Adding one or more surfactants to the composition of step (a);
      • c. Dissolving a cosmetic pharmaceutical and/or active compound in the solvent-polar lipid, surfactant mixture of step (b);
      • d. Adding a urea and at least one thickener to water;
      • e. Combining the compositions from c and d and adjusting the pH to about 5.5 to about 7.5, if necessary.
  • The present disclosure further relates to a composition prepared by the above disclosed method.
  • Other objections and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein it is shown and described only the preferred embodiments, simply by way of illustration of the best mode contemplated of carrying out the disclosure. As will be realized, the disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, without departing from the disclosure. Accordingly, the description is to be regarded as illustrative in nature and not as restrictive.
  • BEST AND VARIOUS MODES
  • By “topical administration”, as used herein, is meant directly laying or spreading upon epidermal or ungual tissue, especially outer skin, nails, or membrane, including the skin or membrane of the oral, rectal, or vaginal cavities.
  • By “safe and effective amount”, as used herein, is meant a sufficient amount of the composition to provide the desired local therapeutic activity and performance at a reasonable benefit/risk ratio attendant any medical treatment. Within the scope of sound medical judgment, the amount of active agent used will vary with the particular condition being treated, the severity of the condition, the duration of the treatment, the specific active ingredient(s) employed, its or their concentration, the condition of the patient, concurrent therapies being administered, and like factors within the specific knowledge and expertise of the patient or the attending physician.
  • By “toxicologically- or pharmacologically-acceptable”, as used herein, is meant the pharmaceutical actives, as well as other compatible drugs, medicaments or inert ingredients which the term describes are suitable for use in contact with the tissues of human and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio.
  • By the term “comprising”, as used herein, is meant that various other compatible cosmetics, drugs and medicaments, as well as inert ingredients, occlusive agents, and cosmetic vehicles, can be conjointly employed in the compositions and methods of this invention, as long as the critical binary penetration enhancement vehicle and cosmetic or pharmaceutical active are used. The term “comprising” thus encompasses and includes the more restrictive terms “consisting of” and “consisting essentially of” which characterize the use of the essential ingredients in the manner disclosed herein.
  • By “afflicted sites”, as used herein, is meant a localized area of pathology, discomfort, infection, inflammation or lesion, and the immediately surrounding area.
  • By “application sites”, as used herein, is meant a site suitable for application via a mechanical sustained release device or dressing, e.g., behind the ear, on the arm, back, top of the foot, etc.
  • By “penetration-enhancing”, as used herein, is meant that the binary penetration enhancing carriers of this disclosure provide marked transepidermal, transungual or percutaneous delivery of an incorporated active, when compared to other compositions at equal chemical potential. This latter aspect is important, since varying solubilities of cosmetics or drugs in different vehicles will necessarily affect their transport across skin or through nails. Thus, for example, if a drug is soluble in vehicle A to the extent of 24%, and in vehicle B to the extent of 4%, were the compositions to be compared at equal percentage concentration, rather than equal chemical potential, the lower solubility carrier will show a misleading six-fold difference in transport over the more soluble vehicle. The simplest way of assuring equal chemical potential for evaluating penetration enhancement is to use saturated solutions or solutions of equal percentage of saturation of pharmacological active in the various vehicles.
  • By “substantially free”, as used herein, is meant that the penetration-enhancing compositions of the present invention contains less than about 10%, preferably less than 3.5%, more preferably less than about 1%, and most preferably less than about 0.5%, of any specific compound, or member of the group of compounds, described by this term.
  • As used herein, all percentages and ratios are by weight of the total composition unless otherwise specified.
  • The terms “active”, “pharmaceutical active”, “pharmacological active”, “pharmaceutical agent”, “pharmacological agent”, “pharmaceutically-, or pharmacologically-active agent”, “chemical agent”, and “therapeutic agent”, are used interchangably herein.
  • The compositions of this disclosure contain a cosmetic agent and/or pharmaceutically-active agent capable of producing or possessing local activity, in a binary vehicle or carrier. The vehicle on carrier comprises a polar lipid, such as lecithin or phosphotidylcholine, and two biocompatible organic solvents, one chosen from the group of esters and one chosen from the group of liquid dihydric and polyhydric alcohols, a preservative, water, a thickener and urea, at a pH of between about 5.5 and 7.5 and preferably between 6.0 and 7.0. The compositions of this disclosure may additionally contain other optional components that reduce skin irritation, or enhance their cosmetic appeal or acceptability, e.g, pigments, fragrances, perfumes, and the like.
  • Typical polar lipids employed are lecithin and phosphotidylcholine. Preferably, the lecithin or phosphatidylcholine is of a high quality, pharmaceutical grade. Appropriate lecithin and phosphatidylcholine maybe obtained as commercially available soya lecithin or soya phosphatidylcholine. Preferably, soya lecithin is used in the composition of this invention.
  • The biocompatible organic ester solvents may be any non-toxic ester in which the polar lipid, the cosmetic or pharmaceutically active compound and urea are soluble, and which assists as a solubilizing vehicle for carrying cosmetic or pharmaceutically active compounds across the skin of a mammal.
  • Typically the esters are fatty mono esters having a structure, obtainable by replacing the active hydrogen of a fatty acid having 4 to 22 carbon atoms and more typically having 8 to 18 carbon atoms by the alkyl group of a monohydric alcohol, particular example being 12 carbon atoms. The fatty acid can be saturated or unsaturated and more typically is saturated. The monohydric alcohol typically contains 2 to 8 carbon atoms and more typically 2 to 5 carbon atoms, a particular example being 3 carbon atoms.
  • Acceptable esters for this purpose include, but are not limited to isopropyl esters. Preferably, the ester is isopropyl myristate or isopropyl palmitate, with isopropyl myristate being particularly preferred.
  • The biocompatible organic dihydric and polyhydric alcohol solvents may be any non-toxic di or polyalcohol in which the polar lipid and the active compound are soluble, and which assists as a solubilizing vehicle for carrying active compounds across the skin of a mammal. Acceptable dihydric and polyalcohols for this purpose include, but are not limited to di- and tri-alcohol alkanes. Typically the alcohols contain 3 to 8 carbon atoms and more typically 3 to 5 carbon atoms and are saturated alcohols. Preferably, the polyalcohol is propylene glycol or glycerol, with propylene glycol being particularly preferred.
  • The compositions of the present disclosure typically contain about 2 to 30% by weight and more typically 4 to 10% by weight of the ester and about 0.5 to about 20% by weight, more typically 1 to about 20% weight, and even more typically 1 to about 10% weight of the alcohol. Many of the compositions contain about 2 to about 20% by weight or, 2 to about 10% weight of the alcohol. Compositions according to the present disclosure exhibit reduced skin irritation.
  • In preparing the composition of this disclosure, the polar lipid is typically dissolved in the organic ester solvent and di or polyalcohol solvent at mass ratios from about 5:1:1 to about 1:5:5. Preferably, the polar lipid and organic ester solvent and polyalcohol solvent are mixed in equal mass ratios. Thus, in one embodiment of the invention, soya lecithin, isopropyl myristate, and propylene glycol are mixed in equal mass ratios and mixed until the lecithin is evenly distributed. This is referred to as the solvent-polar lipid mixture.
  • Depending on the nature of the cosmetic or pharmaceutically active compound and the desired characteristics of the final formulation, a surfactant can be included in the formulation at a concentration of between about 1-20% of the final composition mass. In the formulation including a polycationic active agent, it has been found, according to this disclosure that non-ionic or cationic surfactants are preferred. In the case of other active ingredients, on the other hand, anionic, cationic or non-ionic surfactants are quite acceptable. Preferably, the surfactant is one which is compatible with administration in vivo without elicitation of undesirable side effects. One preferred surfactant is docusate sodium and its more water soluble form, docusate sodium benzoate. Other appropriate ionic or non-ionic surfactants, such as polysorbate 80, Tween 80, docusate calcium, tetradecyltrimethylammonium bromide, pentaoxyetylene glycol monododecyl ether, or triethanolamine laureth sulfate. Once the surfactant is thoroughly dispersed in the solvent-polar lipid mixture, the cosmetic or pharmaceutically active compound may be added and dissolved.
  • The dosage of the cosmetic or pharmaceutical agent will, of course, vary depending upon known factors, such as the cosmetic or pharmaceutical agent characteristics of the particular agent; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired. A daily dosage of active ingredient can be expected to be about 0.001 to 1000 milligrams (mg) per kilogram (kg) of body weight, with the more typical dose being 0.1 to about 30 mg/kg.
  • The active agent is typically present in amounts of about 0.001 to about 30%, more typically about 0.001 to about 20%, and even more typically about 0.5 to 12% by weight based upon the total of the delivery system and active agent. For solid active ingredients, this is most easily achieved by heating an aliquot of the surfactant-solvent-polar lipid mixture and adding, on a mass basis, an amount of active compound equal to about 0.01 to 30% of the mass of the surfactant-solvent-polar lipid and mixing until completely dissolved. Thus, for example, about 1-20 grams of nifedipine in a powdered form is added to about 100 grams of heated 1:0.5:0.5 soya lecithin:isopropyl myristate:propylene glycol and allowed to dissolve with stirring.
  • Some exemplary active agents include vasodilating agents such as glyceryl trinitrate and nifedipine; antimicrobial or antifungal agents such as ciclopirox, itraconazole, metronidazole, miconazole and allylamines such as, naftifine and terbinafine and salts thereof; inhibitors of cell growth or proliferation, such as 2-deoxy-D-glucose; inhibitors of polyamine transport; inhibitors of polyamine synthesis; antizyme inducers; decalcifying skin agents such as lactic acid; anti-inflammatory agents such as ibuprofen and ketoprofen; topical anaesthetics such as lidocaine; steroidal anti-inflammatory compounds, such as cortisone; peptides, proteins, or hormones, such as platelet factor 4; substance P antagonists such as capsaicin; muscle relaxants such as cyclobenzaprine; anti-inflammatory analgesics such as diclofenac sodium and phosphodiesterase inhibitors such as sudenifil.
  • In the event a volatile active agent or proteinaceous active agent is used, adding the active agent to a relatively warm solution of surfactant-solvent polar lipid mixture is not usually desired as this might decrease the amount of active agent in the final formulation.
  • By way of specific examples, in the case of the active nitroglycerin, the active is available in the form of a 10% concentration in propylene glycol, which can be added directly to the polar lipid-solvent-surfactant mixture.
  • The amount of a vasodilator for the treatment of peripheral arterial diseases, including Raynaud's Disease, diabetic paresthesia, and night leg cramps is typically about 0.2 to about 1.8% of the composition.
  • The amount of antimicrobial agent or antifungal agent for the treatment of infectious diseases of the skin and nails, including onychomycosis, athlete's foot, rosacea, and vaginomycosis is typically about 0.5 to about 12% by weight.
  • The amount of an inhibitor of cell growth or proliferation for treatment of actinic keratosis is about 0.001 to about 10% of weight.
  • The amount of an inhibitor of polyamine transport is typically about 0.001 to about 5% by weight. The amount of an inhibitor of polyamine synthesis for the treatment of an automimmune disease, including cutaneous lupus erythrematosus, urticaria, psoriasis, and atopic dermatosis is typically about 0.001 to about 5% by weight.
  • The amount of a decalcifying skin agent, such as lactic acid, for the treatment of dry skin conditions, including xerosis, scleroderma, and ichthyosis is typically about 0.5 to about 10% by weight.
  • It is further understood that two or more different types of active agents can be employed in order to treat more than one condition at the same time. For instance, two or more active agents can be used to treat inflammatory, autoimmune, infectious and/or dry skin conditions simultaneously.
  • After addition of the cosmetic or pharmaceutically active compound, an amount of urea, preferably as a thickened aqueous solution, can be added to the surfactant-solvent-polar lipid mixture. The urea is typically added so that the urea concentration about 1% to about 15% and more typically about 5% and 10% by mass of the final composition mass.
  • The thickener is selected from common National Formulary thickening agents including, but not limited to appropriate polymer weights of polyethylene glycol, polyvinylpyrrolidone, carbomer and methylcellulose. The amount of thickener is typically about 0.05 to about 5% by weight.
  • Thus in a specific example, about 5 grams of a 10% aqueous solution of urea, containing 0.7% Carbomer 934, is added to about 100 grams of the surfactant-solvent-polar lipid mixture with dissolved pharmaceutically active compound. In some instances, the pharmaceutically active agent will more readily dissolve if added after addition of the aqueous urea solution, and in other instances before the addition of aqueous urea solution. In any event, this is a choice readily made by those skilled in the art, once aware of the present disclosure, depending on the particular formulation being prepared and the solubility characteristics of the particular cosmetic or pharmaceutically active compound being solubilized. If the active agent is a protein, it will be necessary to test the retention of biological activity of the protein upon exposure to the particular urea concentration used in this formulation as the chaotropic properties of urea are known to denature some proteins. Such a determination is easily conducted by one of ordinary skill in the art.
  • Upon formulation of the above described composition with the cosmetic or pharmaceutically active agent, the pH is adjusted to typical pH of about 5.5 to about 7.5 and more typically to a 6.0 to 7.0. This can be accomplished, for example, by addition of a base such as aqueous sodium hydroxide and trolamine, as the compositions initially tend to have an acid pH. However, if the pharmaceutically active agent tends to produce very alkaline solutions, addition of an acid to reduce the pH would be desirable. This can be accomplished by addition of an acid such as citric acid or a biological buffer such as sodium carbonate or potassium phosphate. With the composition in a pH range of about 5.5 to 7.5, the formulation thickens and forms a smooth, viscous gel for topical administration.
  • In one embodiment of the disclosure, the composition is formulated with a vasodilating agent, such as glyceryl trinitrate. Such formulation is rapidly absorbed through the skin and provides local vasodilation, increases in blood flow, and restoration of normal temperature to an extremity with low blood flow. In another embodiment of the invention, the composition is formulated with an anti-infective agent. Such formulation is rapidly absorbed through the skin, or somewhat more slowly through the nails to provide local delivery to kill invading microorganisms such as fungi or bacteria.
  • By routine experimentation, using the recited elements of this composition, those skilled in the art, once aware of the present disclosure, will be able to make specific gels of essentially any active ingredient or combination thereof for a wide variety of typical applications. In addition, it is understood that the compositions can contain auxiliary agents including those conventionally known and/or used in this art such as, but not limited to, preservatives and fragrances.
  • For ease of preparation, it is convenient to prepare a first gel composition, referred to herein as “MQX-GEL”, which can be used to add to other components in the formulation of a final composition for topical administration. There are several possible formulations of the MQX-GEL. For example, a MQX-GEL may be prepared by mixing lecithin organogel (L.O.), as a 1:1:1 (m/m/m) mixture of lecithin, isopropyl myristate and propylene glycol, with LID oil (a 1:1 [m/m] mixture of L.O. and docusate sodium), dissolving additional surfactant and/or docusate sodium powder into this mixture, and then adding thickened aqueous urea.
  • In one embodiment of the MQX-GEL formulation, the final concentrations are: L.O.=30%; docusate sodium=9%; urea=5%; thickener=1%; and water=55%. These ratios may easily be varied such that the final amounts of each component are as follows: L.O.=15-50%; docusate sodium and/or another surfactant=3-15%; urea=1-15%; thickener=0.5-5%; and water=40-65%. The solubilized active ingredients may then be added to MQX-GEL. Excipients which may be useful in solubilizing the active ingredient include L.O., propylene glycol, isopropyl myristate, peppermint oil, glycerin, and/or polyethylene glycol. A homogenous mixture is then made by carefully blending the various components.
  • Once the formulations described above have been prepared, use of the formulations is a simple matter of applying the formulation to affected areas where cutaneous delivery of the pharmaceutically active agent is desired. Thus, in the case of Raynaud's phenomenon, formulations containing glyceryl trinitrate are rubbed over the affected area such as the fingers of the hands. Treatment is repeated as symptoms reappear or when used as a prophylactic treatment, just before symptoms may appear. In use of formulations prepared according to this invention, normal blood flow in the fingers of the Raynaud's patient has been restored within five minutes of application.
  • In another aspect of this invention, an anti-fungal anti-microbial compound is formulated for delivery to toe nails infected with fungus. In nine-month treatments, doctors and patients across the country have confirmed almost complete reduction in fungal infection. This is in contrast to results observed with current commercial topical formulations with this same active ingredient that provide very modest reduction in fungal infection in the same time frame.
  • A still further indication for the organogel compositions of this disclosure is for treating nail psoriasis. For such indication, active ingredients to use include one or more of the compounds useful in the treatment of psoriasis, typically in amounts of about 0.0005% to 10% depending upon the type of agent, such as, corticosteroids (Clobetasol propionate about 0.005-about 0.05%, Betamethasone dipropionate about 0.005-about 0.05%, Diflorasone diacetate about 0.005-about 0.05%, Halcinonide about 0.01-about 0.1%, Desoximetasone about 0.005-about 0.5%, Triamcinolone acetonide about 0.01-about 0.5%), anti-proliferative cancer agents (flourouracil, methotrexate, polyamine synthesis and transport inhibitors, antizyme inducers, each about 0.05-about 5.0%), retinoids (tazarotene, acetretin), vitamin D analogs (calcipotriene); combinations of these agents and also a combination with an antifungal agent (e.g. miconazole, ciclopirox, terbinafine, each at about 0.5-about 10%).
  • In another aspect of this invention, a composition comprising an antibacterial agent is prepared, for example, by inclusion of bacitracin or another appropriate antibiotic. This allows for penetration of the antibacterial agent to sites of infection induced by puncture wounds.
  • In general, compositions of this invention are provided at a concentration of between about 0.001% to 30% by weight of active compound. In addition, compositions comprising more than one active ingredient are within the scope of this disclosure and could be administered to a recipient in need of more than a single active treatment at one localized spot. Thus, for example, a composition comprising a vasodilating agent and an antifungal would both provide relief from fungal infection and will facilitate long-term relief by restoring blood flow and the flow of nutrients to the affected area.
  • It is contemplated that the compositions of this disclosure are applied topically as frequently as required as long as local reactions or toxicity due to the active ingredient do not become a problem. Thus, for example, a more rigorously monitored regimen of application may be required when an anti-neoplastic compound is being administered than when a readily metabolized non-toxic compound such as ketoprofen is administered. In the latter case, it would be acceptable for a person in need of such treatment to topically apply the composition as frequently as needed to achieve relief from local pain or inflammation.
  • While the foregoing description generally describes how to make and use the compositions and formulations of this disclosure, the following examples are provided to more specifically point out how to practice the invention. However, it should be clearly understood that the scope of this disclosure, as defined by the claims appended hereto, is not to be limited to the specifics of the following examples. Further, it should be understood that, in the specific compositions described and claimed, the percentages of active and other ingredients could be within at least a 10% different amount while still achieving an objective equivalent to the specifically disclosed compositions.
  • The following non-limiting examples are presented to further illustrate the present disclosure:
  • EXAMPLE 1 Preparation of MQX-GEL
  • 500 gm
    LID Oil* 50 gm
    Lecithin organogel** (L.O.) 100 gm
    Docusate sodium powder 50 gm
    Urea 50 gm
    Thickener 5 gm
    Distilled water 245 ml
    *LID oil is a 1:1 mixture of lecithin organogel:docusate sodium on a mass basis.
    **L.O. is a 1:1:1 mixture of lecithin, isopropyl myristate and propylene glycol.
  • 1. The LID was added to L.O. and heated.
  • 2. Docusate sodium powder was added, and the mixture was stirred until smooth.
  • 3. Thickener and urea were completely dissolved in water, heated, and added to step 2 with stirring.
  • 4. pH was adjusted to between 6.5 to 6.9.
  • MQX-GEL may just as easily be prepared as follows:
  • 1000 gm
    L.O. 250 gm
    Docusate sodium benzoate powder 150 gm
    Urea 100 gm
    Thickener 10 gm
    Distilled water 490 ml
  • The L.O. was heated and the docusate sodium benzoate powder was stirred into the heated L.O. until a smooth solution is prepared. The water was heated and the thickener and urea were dissolved into the water, and the thickened urea solution was then thoroughly mixed with the docusate sodium containing solution of L.O. The result was a consistent, transparent, amber colored gel with a pH of about 6.0.
  • A further method of making MQX-GEL is as follows:
  • 1000 gm
    L.O. 100 gm
    LID 300 gm
    Urea 100 gm
    Thickener  10 gm
    Distilled water 490 gm
  • The LID and L.O. were mixed well and a heated solution of water, the thickener and the urea was prepared and added to the LID-L.O. solution. The result was a consistent, transparent, amber colored gel with a pH of about 6.0.
  • EXAMPLE 2 Preparation of 1.2% Glyceryl Trinitrate Gel
  • 500 gm
    Glyceryl Trinitrate 6.0 gm
    (as 10% active in propylene glycol
    or 54.0 gm of propylene glycol)
    Lecithin organogel (L.O.) 90.0 gm
    Docusate Sodium 22.6 gm
    Urea 25.1 gm
    Carbomer 934 3.5 gm
    Methylcellulose 4.4 gm
    Water, distilled 294.4 gm
  • 1. Docusate sodium is added to L.O. and stirred to obtain a clear solution.
  • 2. Glyceryl trinitrate (as 10% active in propylene glycol) is added to solution of step 1.
  • 3. Urea is added to distilled water, with heating and stirring to obtain a uniform solution.
  • 4. Carbomer 934 and Methylcellulose are added to thicken the urea-water of step 3.
  • 5. The lecithin organogel with the active component from step 2 is combined with the thickened aqueous urea from step 4 to form a uniform mixture.
  • 6. The pH is adjusted to 6.5 with dilute aqueous NaOH to form an elegant thick gel.
  • EXAMPLE 3 Preparation of 0.5% Glyceryl Trinitrate Gel
  • 500 gm
    Glyceryl Trinitrate 2.5 gm
    (as 10% active in propylene glycol
    or 22.5 gm of propylene glycol)
    Lecithin organogel (L.O.) 125.0 gm
    Docusate Sodium 22.6 gm
    Urea 25.1 gm
    Carbomer 934 3.5 gm
    Methylcellulose 4.4 gm
    Water, distilled 294.4 gm
  • The same method of combining the ingredients is used as described in example 2.
  • MQX-GEL can also be prepared with other ratios of the three constituents of the lecithin organogel. In the following example, the ratio of lecithin organogel (L.O.#2), is a 1:0.9:0.1 (m/m/m) mixture of lecithin, isopropyl myristate and propylene glycol, with LID oil (a 1:1 [m/m] mixture of L.O.#2 and docusate sodium), dissolving additional surfactant and/or docusate sodium powder into this mixture, and then adding thickened aqueous urea.
  • In this embodiment of the MQX-GEL formulation, the final concentrations are: L.O.#2=25%; docusate sodium=10%; urea=10%; thickener=1%; and water=54%. These ratios also may easily be varied such that the final amounts of each component are as follows: L.O.#2=15-50%; docusate sodium and/or another surfactant=3-15%; urea=1-15%; thickener=0.5-5%; and water=40-65%. The solubilized active ingredients may then be added to MQX-GEL. Excipients which may be useful in solubilizing the active ingredient include L.O.#2, propylene glycol, isopropyl myristate, peppermint oil, glycerin, and/or polyethylene glycol. A homogenous mixture is then made by carefully blending the various components.
  • EXAMPLE 4 Preparation of another 1.2% Glyceryl Trinitrate Gel
  • 500 gm
    Glyceryl Trinitrate 6.0 gm
    (as 10% active in propylene glycol
    or 54.0 gm of propylene glycol)
    L.O. #2 115.0 gm
    Docusate Sodium 45.0 gm
    Urea 45.0 gm
    Carbomer 934 3.5 gm
    Methylcellulose 4.4 gm
    Water, distilled 227.1 gm
  • The same method of combining the ingredients is used as in example 2.
  • EXAMPLE 5 Preparation of 0.5% Glyceryl Trinitrate Gel
  • 500 gm
    Glyceryl Trinitrate 2.5 gm
    (as 10% active in propylene glycol
    or 22.5 gm of propylene glycol)
    L.O.#2 150.0 gm
    Docusate Sodium 45.0 gm
    Urea 45.0 gm
    Carbomer 934 3.5 gm
    Methylcellulose 4.4 gm
    Water, distilled 227.1 gm
  • The same preparation method was used in this example as in the previous one.
  • EXAMPLE 6 Preparation of 8.0% Ciclopirox Gel
  • 500 gm
    Ciclopirox 40.0 gm
    L.O.#2 128.9 gm
    Docusate Sodium 45.0 gm
    Urea 45.0 gm
    Carbomer 934 2.6 gm
    Methylcellulose 1.5 gm
    Water, distilled 237.0 gm
  • 1. Docusate sodium is added to L.O.#2 and stirred to obtain a clear solution.
  • 2. Ciclopirox is added to solution of step 1.
  • 3. Urea is added to distilled water, with heating and stirring to obtain a uniform solution.
  • 4. Carbomer 934 and Methylcellulose are added to thicken the urea-water of step 3.
  • 5. The lecithin organogel with the active from step 2 is combined with the thickened aqueous urea from step 4 to form a uniform mixture.
  • 6. The pH is adjusted to 6.5 with dilute aqueous NaOH to form an elegant thick gel.
  • EXAMPLE 7 Preparation of 15.0% Lactic Acid Gel
  • 500 gm
    Lactic Acid 75.0 gm
    L.O.#2 118.9 gm
    Docusate Sodium 30.0 gm
    Urea 45.0 gm
    Carbomer 934 2.6 gm
    Methylcellulose 1.5 gm
    Water, distilled 232.0 gm
  • The same method of preparation is used as in example 6.
  • EXAMPLE 8 Preparation of 8% Ciclopirox, 1% Glyceryl Trinitrate Gel
  • 500 gm
    Glyceryl Trinitrate 5.0 gm
    (as 10% active in propylene glycol
    or 45.0 gm of propylene glycol)
    Ciclopirox 40.0 gm
    L.O. #2 115.0 gm
    Docusate Sodium 35.0 gm
    Urea 35.0 gm
    Carbomer 934 2.8 gm
    Methylcellulose 1.7 gm
    Water, distilled 220.5 gm
  • 1. Docusate sodium is added to L.O.#2 and stirred to obtain a clear solution.
  • 2. Ciclopirox and Glyceryl trinitrate, as 10% solution in propylene glycol, is added to solution of step 1.
  • Urea is added to distilled water, with heating and stirring to obtain a uniform solution.
  • 4. Carbomer 934 and Methylcellulose are added to thicken the urea-water of step 3.
  • 5. The lecithin organogel with the actives from step 2 is combined with the thickened aqueous urea from step 4 to form a uniform mixture.
  • 6. The pH is adjusted to 6.5 with dilute aqueous NaOH to form an elegant thick gel.
  • EXAMPLE 9 Preparation of 10% Ibuprofen, 0.5% Glyceryl Trinitrate Gel
  • 500 gm
    Glyceryl Trinitrate 2.5 gm
    (as 10% active in propylene glycol
    or 22.5 gm of propyleneglycol)
    Ibuprofen 50.0 gm
    L.O. #2 135.0 gm
    Docusate Sodium 15.0 gm
    Urea 35.0 gm
    Carbomer 934 2.8 gm
    Methylcellulose 1.7 gm
    Water, distilled 220.5 gm
  • 1. Docusate sodium and ibuprofen are added to L.O.#2 and stirred to obtain a clear solution.
  • 2. Glyceryl trinitrate, as 10% solution in propylene glycol, is added to solution of step 1.
  • 3. Urea is added to distilled water, with heating and stirring to obtain a uniform solution.
  • 4. Carbomer 934 and Methylcellulose are added to thicken the urea-water of step 3.
  • The lecithin organogel with the actives from step 2 is combined with the thickened aqueous urea from step 4 to form a uniform mixture.
  • The pH is adjusted to 6.5 with dilute aqueous NaOH to form an elegant thick gel.
  • EXAMPLE 10 Preparation of 5.0% 2-Deoxy-D-Glucose Gel
  • 500 gm
    2-Deoxy-D-Glucose 25.0 gm
    L.O.#2 128.9 gm
    Docusate Sodium 45.0 gm
    Urea 45.0 gm
    Carbomer 934 2.6 gm
    Methylcellulose 1.5 gm
    Water, distilled 252.0 gm
  • 1. Docusate sodium is added to L.O.#2 and stirred to obtain a clear solution.
  • 2. 2-Deoxy-D-Glucose is added to solution of step 1.
  • 3. Urea is added to distilled water, with heating and stirring to obtain a uniform solution.
  • 4. Carbomer 934 and Methylcellulose are added to thicken the urea-water of step 3.
  • 5. The lecithin organogel with the active from step 2 is combined with the thickened aqueous urea from step 4 to form a uniform mixture.
  • 6. The pH is adjusted to 6.5 with dilute aqueous NaOH to form an elegant thick gel.
  • Additional formulations for treating onychomycosis that can be prepared along the lines of Example 6 are presented below.
  • EXAMPLE 11 Formulation of 2% Miconazole Gel
  • A formulation is prepared along the lines of Example 6 containing 2% miconazole nitrate, 48.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • EXAMPLE 12 Formulation of 2% Naftifine Gel
  • A formulation is prepared along the lines of Example 6 containing 2% naftifine hydrochloride, 48.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • EXAMPLE 13 Formulation of 5% Terbinafine Gel
  • A formulation is prepared along the lines of Example 6 containing 5% terbinafine hydrochloride, 45.5% distilled water, 9.75% urea, 0.7% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • EXAMPLE 14 Formulation of 2% Ciclopirox Gel
  • A formulation is prepared along the lines of Example 6 containing 2% ciclopirox olamine, 48.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • EXAMPLE 15 Formulation of 4% Ciclopirox Gel
  • A formulation is prepared along the lines of Example 6 containing 4% ciclopirox olamine, 46.5% distilled water, 10% urea, 0.45% carbopol, 8.8% isopropyl myristate, 9.8% lecithin, 19.1% docusate sodium, 0.4% polysorbate 80, 1.0% propylene glycol, 0.8% trolamine and 0.12% 1.0 N NaOH.
  • EXAMPLE 16 Formulation of 0.001% Betamethasone Dipropionate and 2.5% Methotrexate for Treating Nail Psoriasis
  • A formulation along the lines of example 11 can be prepared by replacing the 2% miconazole with 0.001% betamethasone dipropionate and 2.5% methotrexate.
  • EXAMPLE 17 Formulation of 0.001% Betamethasone Dipropionate, 2.5% Methotrexate, and 2% Miconazole for Treating Nail Psoriasis
  • A formulation along the lines of example 11 can be prepared by replacing the 2% miconazole with 0.001% betamethasone dipropionate, 2.5% methotrexate, and 2% miconazole.
  • The foregoing description illustrates and describes the present disclosure. Additionally, the disclosure shows and describes only the preferred embodiments of the disclosure, but, as mentioned above, it is to be understood that it is capable of changes or modifications within the scope of the concept as expressed herein, commensurate with the above teachings and/or the skill or knowledge of the relevant art. The embodiments described hereinabove are further intended to explain best modes known of practicing the invention and to enable others skilled in the art to utilize the disclosure in such, or other, embodiments and with the various modifications required by the particular applications or uses disclosed herein. Accordingly, the description is not intended to limit the invention to the form disclosed herein. Also, it is intended that the appended claims be construed to include alternative embodiments.
  • All publications, patents and patent applications cited in this specification are herein incorporated by reference, and for any and all purposes, as if each individual publication, patent or patent application were specifically and individually indicates to be incorporated by reference. In the case of inconsistencies, the present disclosure will prevail.

Claims (34)

1. A composition suitable for the delivery of at least one cosmetic agent or pharmaceutical agent or both through the skin or nails of a mammal, which comprises two biocompatible organic solvents, 6 to 30% by weight of lecithin, 0.5 to 19% by weight of at least one or more surfactant, wherein said surfactant comprises a docusate, 40 to 65% by weight of water, 1 to 15% by weight of urea and 0.05 to 5% by weight of thickener; wherein the organic solvents comprise 2 to 30% of isopropyl myristate and 0.5 to 20% of glycerol.
2. The composition of claim 1, wherein at least one surfactant is selected from the group consisting of docusate sodium, docusate sodium benzoate, and docusate calcium.
3. The composition according to claim 1, wherein the thickener is selected from the group of polyethylene glycol, methyl cellulose, and carbomer.
4. The composition of claim 1, wherein further contains at least one of a cosmetic agent or pharmaceutical agent or both.
5. The composition of claim 1, wherein the amount of the cosmetic agent or pharmaceutical agent or both is about 0.001 to about 30% by weight.
6. The composition of claim 1, having a pH of about 5.5 to about 7.5.
7. The composition of claim 1, wherein the pH is about 6 to about 7.
8. The composition of claim 1, further comprising at least 0.2-1.8% of a vasodilating agent.
9. The composition of claim 1, wherein the vasodilating agent is glyceryl trinitrate.
10. The composition of claim 1, further comprising about 1 to about 12% of an antimicrobial agent.
11. The composition of claim 10, wherein the antimicrobial agent is selected from the group consisting of ciclopirox, miconazole, itraconazole, metronidazole, an allylamine and mixtures thereof and pharmaceutically acceptable salts thereof.
12. The composition of claim 10, wherein the antimicrobial agent is selected from the group consisting of ciclopirox, miconzaole, terbinafine and naftifine and mixtures thereof and salts thereof.
13. The composition of claim 1, further comprising about 0.001-10.0% of an inhibitor of cell growth or proliferation.
14. The composition of claim 13, wherein said inhibitor is 2-deoxy-D-glucose.
15. The composition of claim 1, further comprising about 0.001-5.0% of an inhibitor of polyamine transport or 0.005-5.0% of an inhibitor of polyamine synthesis.
16. The composition of claim 1, further comprising about 0.001-5.0% of an antizyme inducer.
17. The composition of claim 1, further comprising about 0.5-10% of a decalcifying skin agent.
18. The composition of claim 17, wherein the decalcifying skin agent is lactic acid.
19. The composition of claim 1, further comprising an effective amount of one or more psoriasis treating agent(s).
20. The composition, according to claim 19, wherein the psoriasis treating agent comprises betamethasone dipropionate or methotrexate or both.
21. The composition, according to claim 19 which further comprises metronidazole.
22. The composition, according to claim 1, further comprising at least two active ingredients.
23. A method of delivering an active agent into and through the epidermis tissue of a human or animal which comprises topically applying to the skin of the human or animal a composition according to claim 4.
24. A method for treating a patient suffering from onychomycosis which comprises topically applying to the patient's nail(s) infected with fungus a composition according to claim 11.
25. A method of treating a patient suffering from onychomycosis which comprises topically applying to the patient's nail(s) infected with fungus a composition according to claim 12.
26. A method of making a composition suitable for cutaneous delivery of at least one cosmetic agent or a pharmaceutical agent or both wherein said composition comprises at least one cosmetic agent or a pharmaceutical agent or both, two biocompatible organic solvents 6 to 30% by weight of lecithin, 0.5 to 19% by weight of at least one or more surfactant, wherein said surfactant comprises a docusate, about 40 to about 65% by weight water, 1 to 15% by weight of urea and 0.5 to 5% by weight of a thickener; wherein the organic solvents comprise 2 to 30% of isopropyl myristate and 0.5 to 20% of glycerol; and which method comprises:
a. dissolving 6 to 30% by weight of lecithin, at least in two biocompatible organic solvents comprising isopropyl myristate and glycerol;
b. adding 0.5 to 19% by weight of one or more surfactants to the composition of step (a); wherein said one or more surfactants comprises a docusate;
c. dissolving a cosmetic agent or pharmaceutically active compound or both in the solvent-polar lipid, surfactant mixture of step (b);
d. adding 1 to 15% by weight of urea and 0.5 to 5% by weight of thickener(s) to water; and
e. combining the composition from c and d and optionally adjusting the pH to about 5.5 to about 7.5.
27. A composition prepared according to the method of claim 26.
28. A method of making a composition suitable for cutaneous delivery of at least one cosmetic agent or a pharmaceutical agent or both wherein said composition comprises at least one cosmetic agent or a pharmaceutical agent or both, two biocompatible organic solvents, 6 to 30% by weight of lecithin, 0.5 to 19% by weight of at least one or more surfactant, wherein said surfactant comprises a docusate, 40 to 65% by weight water, 1 to 15% by weight of urea and 0.5 to 5% by weight of a thickener; wherein the organic solvents comprise 2 to 30% of isopropyl myristate and 0.5 to 20% of glycerol; and which method comprises:
a. dissolving 16 to 30% by weight of lecithin , at least in two biocompatible organic solvents comprising isopropyl myristate and glycerol;
b. adding 0.5 to 19% by weight of one or more surfactants to the composition of step (a); wherein said one or more surfactants comprises a docusate;
c. adding 1 to 15% by weight of urea and 0.5 to 5% by weight of thickener(s) to water;
d. dissolving a cosmetic agent or pharmaceutically active compound or both in the thickened aqueous urea; and
e. combining the composition from (b) and (d) and optionally adjusting the pH to about 5.5 to about 7.5.
29. A composition prepared according to the method of claim 28.
30. A method for treating a patient suffering from nail psoriasis which comprises topically applying to the patient's nail(s) a composition according to claim 19.
31. A method for treating a patient suffering from nail psoriasis which comprises topically applying to the patient's nail(s) a composition according to claim 21.
32. A method for treating a patient for infections which comprises topically applying to the patient a composition according to claim 1 that further comprises an effective amount of an antibacterial agent.
33. The method of claim 28, wherein said at least one surfactant is selected from the group consisting of docusate sodium, docusate sodium benzoate, and docusate calcium, the thickener is selected from the group of polyethylene glycol, methyl cellulose, and carbomer.
34. The method of claim 26, wherein said at least one surfactant is selected from the group consisting of docusate sodium, docusate sodium benzoate, and docusate calcium, the thickener is selected from the group of polyethylene glycol, methyl cellulose, and carbomer.
US12/856,292 2004-10-08 2010-08-13 Organo-gel formulations for therapeutic applications Abandoned US20100305081A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/856,292 US20100305081A1 (en) 2004-10-08 2010-08-13 Organo-gel formulations for therapeutic applications

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/960,516 US7740875B2 (en) 2004-10-08 2004-10-08 Organo-gel formulations for therapeutic applications
US11/066,485 US20060078579A1 (en) 2004-10-08 2005-02-28 Organo-gel formulations for therapeutic applications
US11/150,254 US20060078580A1 (en) 2004-10-08 2005-06-13 Organo-gel formulations for therapeutic applications
US11/246,296 US7776349B2 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications
US12/856,292 US20100305081A1 (en) 2004-10-08 2010-08-13 Organo-gel formulations for therapeutic applications

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/246,296 Continuation US7776349B2 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications

Publications (1)

Publication Number Publication Date
US20100305081A1 true US20100305081A1 (en) 2010-12-02

Family

ID=36148664

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/150,254 Abandoned US20060078580A1 (en) 2004-10-08 2005-06-13 Organo-gel formulations for therapeutic applications
US11/246,296 Active 2027-09-17 US7776349B2 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications
US12/856,292 Abandoned US20100305081A1 (en) 2004-10-08 2010-08-13 Organo-gel formulations for therapeutic applications

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11/150,254 Abandoned US20060078580A1 (en) 2004-10-08 2005-06-13 Organo-gel formulations for therapeutic applications
US11/246,296 Active 2027-09-17 US7776349B2 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications

Country Status (8)

Country Link
US (3) US20060078580A1 (en)
EP (1) EP1796632A4 (en)
JP (1) JP2008515911A (en)
KR (1) KR20070072482A (en)
AU (1) AU2005294216C1 (en)
BR (1) BRPI0512583B8 (en)
CA (1) CA2567575C (en)
WO (1) WO2006042059A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510855B2 (en) 2018-09-27 2022-11-29 Dermaliq Therapeutics, Inc. Topical sunscreen formulation

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1526837A1 (en) * 2002-07-24 2005-05-04 Basf Aktiengesellschaft Ascorbic acid salt suspensions and use thereof as antioxidants
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
ES2288133B1 (en) * 2006-06-12 2008-09-16 Maria Cristina Fernandez Rodriguez TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS.
CA2676975A1 (en) * 2007-02-05 2008-08-14 Biophile Corporation, Ltd. Increased effectiveness of allylamine drug compounds
EP1958639A1 (en) * 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
GB0720716D0 (en) * 2007-10-23 2007-12-05 York Pharma Plc Novel formulation
WO2009054992A1 (en) * 2007-10-25 2009-04-30 Ivrea Pharmaceuticals, Inc. Antimicrobial compositions comprising docusate
US20090191138A1 (en) * 2008-01-30 2009-07-30 Mediquest Therapeutics, Inc. Novel topical formulations for improving the appearance of nails
US20100016446A1 (en) * 2008-07-21 2010-01-21 Sylvia Gonda Stable water-based topical pharmaceutical creams and methods of making and using same
JP2011529038A (en) * 2008-07-23 2011-12-01 ターゲッティド デリバリー テクノロジーズ リミテッド Method of administering topical antifungal formulations for the treatment of fungal infections
WO2010047831A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
CN103349285A (en) * 2008-11-14 2013-10-16 阿彻丹尼尔斯米德兰德公司 Rganogel compositions and processes for producing
CA2751412A1 (en) * 2009-02-05 2010-08-12 Targeted Delivery Technologies Limited Methods of reducing the proliferation and viability of microbial agents
JP5582467B2 (en) * 2009-04-23 2014-09-03 学校法人日本大学 Oil gel consisting of reverse string micelle based on lecithin and urea
US20100273834A1 (en) * 2009-04-25 2010-10-28 Reza Babapour Treatment of onychomycosis and related compositions including urea
CA2785643A1 (en) * 2009-12-23 2011-06-30 Nuvo Research Inc. Highly permeating terbinafine formulation
JP5816636B2 (en) 2010-03-17 2015-11-18 ノバリック ゲーエムベーハー Pharmaceutical composition for the treatment of elevated intraocular pressure
BR112012029040A2 (en) * 2010-05-14 2016-08-02 Archer Daniels Midland Co edible heat-reversible structured phospholipid organogel composition for use in a food product, method of structuring an edible organic phase, food product or ingredient, composition, method of loading an edible heat-reversible structured phospholipid organogel, method of coating a food and edible heat-resistant structured phospholipid for use in a food product
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012151427A1 (en) * 2011-05-03 2012-11-08 Aponia Laboratories, Inc. Transdermal compositions of ibuprofen and methods of use thereof
WO2012160179A2 (en) 2011-05-25 2012-11-29 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
WO2013072929A2 (en) 2011-09-23 2013-05-23 Indian Institute Of Technology Nanop article based cosmetic composition
ES2625538T3 (en) 2012-01-23 2017-07-19 Novaliq Gmbh Stabilized protein compositions based on semi-fluorinated alkanes
PT2895144T (en) 2012-09-12 2017-02-22 Novaliq Gmbh Semifluorinated alkane compositions
MY166228A (en) 2012-09-12 2018-06-22 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
WO2014126173A1 (en) 2013-02-13 2014-08-21 国立大学法人九州大学 Gelatinizer and organogel
EP2815757A1 (en) * 2013-06-17 2014-12-24 Hestia Investments Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa
DK3024484T3 (en) 2013-07-23 2018-10-08 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
WO2016144121A2 (en) * 2015-03-12 2016-09-15 동아제약 주식회사 Pharmaceutical composition for treating fungal infectious diseases of ketratin tissue
KR101690765B1 (en) * 2015-04-17 2016-12-28 동아제약 주식회사 Transdermal formulation comprising antifungal agent
ES2803248T3 (en) 2015-09-30 2021-01-25 Novaliq Gmbh 2-perfluorohexyl octane for ophthalmic administration
PL3355990T3 (en) 2015-09-30 2019-11-29 Novaliq Gmbh Semifluorinated compounds and their compositions
EP3442480B1 (en) 2016-06-23 2019-10-02 Novaliq GmbH Topical administration method
JP7012075B2 (en) 2016-09-22 2022-01-27 ノバリック ゲーエムベーハー Pharmaceutical composition for use in the treatment of blepharitis
CA3036306A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
US11273174B2 (en) 2017-04-21 2022-03-15 Novaliq Gmbh Iodine compositions
CN110650734A (en) 2017-05-12 2020-01-03 诺瓦利克有限责任公司 Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of conditions associated with contact lenses
WO2019063551A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
US20220354783A1 (en) 2018-08-01 2022-11-10 Edix-O Sarl Injectable prolonged-action compositions for use in the treatment of nail disease and/or for promoting nail growth
EP3603650A1 (en) 2018-08-01 2020-02-05 Edix O Sarl Injectable and prolonged action compositions for use in the treatment of diseases of the nail and/or to accelerate nail growth
CN112823020A (en) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 Ophthalmic compositions for treating dry eye
US11813354B1 (en) * 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone

Citations (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
US4567161A (en) * 1982-07-09 1986-01-28 A. Natterman & Cie Gmbh Liquid active ingredient concentrates for preparation of microemulsions
US4684661A (en) * 1984-11-22 1987-08-04 Sandoz Ltd. Anti-fungal homopropargylamines, compositions, and method of use therefor
US4751245A (en) * 1986-06-25 1988-06-14 E. R. Squibb & Sons, Inc. Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same
US4755534A (en) * 1979-08-22 1988-07-05 Sandoz Ltd. Propenylamines, pharmaceutical compositions containing them and their use as pharmaceuticals
US4764381A (en) * 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US4788061A (en) * 1985-07-05 1988-11-29 Shore Ronald N Extended occlusive treatment of skin disorders
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4920112A (en) * 1988-04-18 1990-04-24 Merck & Co., Inc. Fungicidal compositions and method
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US5030625A (en) * 1984-11-22 1991-07-09 Sandoz Ltd. Anti-fungal homopropargylamine compounds
US5045317A (en) * 1987-07-16 1991-09-03 The Regents Of The University Of California Enhancing the cutaneous penetration of pharmacologically active agents
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US5132459A (en) * 1979-08-22 1992-07-21 Sandoz Ltd. Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US5231183A (en) * 1989-10-02 1993-07-27 Banyu Pharmaceutical Co., Ltd. Process for producing enyne derivatives
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5385911A (en) * 1990-12-18 1995-01-31 Merrell Dow Pharmaceuticals Inc. Anti-herpes castanospermine esters
US5401742A (en) * 1993-05-11 1995-03-28 Japan, As Represented By Director General Of Agency Of Industrial Science And Technology Polymeric conjugate of methotrexate compound and pyran copolymer and method for the preparation thereof
US5591774A (en) * 1986-12-23 1997-01-07 Yu; Ruey J. Method of treating wrinkles using malic acid
US5639740A (en) * 1995-03-10 1997-06-17 Crandall; Wilson Trafton Topical moisturizing composition and method
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5693676A (en) * 1994-05-27 1997-12-02 Neptune Pharmaceutical Corporation Nitric oxide donor composition and method for treatment of anal disorders
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5741513A (en) * 1990-02-08 1998-04-21 A. Natterman & Cie. Gmbh Alcoholic aqueous gel-like phospholipid composition, its use and topical preparations containing it
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US5814305A (en) * 1991-03-08 1998-09-29 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US5817875A (en) * 1995-09-20 1998-10-06 Karimian; Khashayar Methods for the manufacture of terbinafine
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
US5985906A (en) * 1995-05-12 1999-11-16 Novartis Ag Antifungal composition
US5993790A (en) * 1997-08-04 1999-11-30 Pedinol Pharmacal Inc. Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections
US6017920A (en) * 1994-05-06 2000-01-25 Toko Yakuhin Kogyo Kabushiki Kaisha Antifungal composition for external use being retentive in stratum corneum
US6042845A (en) * 1994-12-22 2000-03-28 Johnson & Johnson Consumer Products, Inc. Anti fungal treatment of nails
US6143794A (en) * 1998-04-17 2000-11-07 Bertek Pharmaceuticals, Inc. Topical formulations for the treatment of nail fungal diseases
US6165975A (en) * 1997-06-23 2000-12-26 Queen's University At Kingston Microdose therapy
US6172261B1 (en) * 1997-07-15 2001-01-09 Oridigm Corporation Polyamine analogues as therapeutic and diagnostic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6281239B1 (en) * 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
US6287601B1 (en) * 1996-11-19 2001-09-11 Meri Charmyne Russell Topical nitric oxide donor compositions
US6316428B1 (en) * 1995-03-10 2001-11-13 Wilson Trafton Crandall Topical moisturizing composition and method
US20010056071A1 (en) * 2000-03-24 2001-12-27 Pelliccia Maria Teresa Use of resveratrol for the treatment of exfoliative eczema, acne and psoriasis
US6538017B2 (en) * 2001-03-09 2003-03-25 Ortho-Mcneil Pharmaceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
US6596287B2 (en) * 1997-05-27 2003-07-22 Semibiosys Genetics Inc. Products for topical applications comprising oil bodies
US20030181526A1 (en) * 2002-03-20 2003-09-25 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US20030181525A1 (en) * 2002-03-20 2003-09-25 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US6632843B1 (en) * 2000-02-01 2003-10-14 Mark Friedman Treatment of bruxism
US20030235541A1 (en) * 2002-06-21 2003-12-25 Maibach Howard I. Topical administration of basic antifungal compositions to treat fungal infections of the nails
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20040096410A1 (en) * 2002-07-29 2004-05-20 Maley Joseph C. Methods and compositions for treatment of dermal conditions
US20040101538A1 (en) * 2001-03-30 2004-05-27 Catherine Larnier Topical composition
US6743417B2 (en) * 2002-04-22 2004-06-01 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis with urea and an antioxidant
US20040197280A1 (en) * 2001-10-22 2004-10-07 Repka Michael A. Delivery of medicaments to the nail
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050074414A1 (en) * 2002-10-25 2005-04-07 Foamix Ltd. Penetrating pharmaceutical foam

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883545A (en) * 1968-08-31 1975-05-13 Hoechst Ag Certain 1-hydroxy-2-pyridones
US4021573A (en) * 1974-04-22 1977-05-03 The Regents Of The University Of California Psoriasis treatment with retinoic acid analogs
US4036970A (en) * 1975-07-28 1977-07-19 Syntex (U.S.A.) Inc. Imidazol-1-yl propane derivatives
FR2502951B1 (en) 1981-04-06 1985-12-06 Sandoz Sa TOPICAL PHARMACEUTICAL COMPOSITIONS IN THE FORM OF A MICRO-EMULSION
DE3544983A1 (en) * 1985-12-19 1987-06-25 Hoechst Ag ANTIMYCOTIC EFFECTIVE NAIL POLISH
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US4782059A (en) 1986-09-29 1988-11-01 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
GB8630721D0 (en) * 1986-12-23 1987-02-04 Unilever Plc Cosmetic compositions
DE3720147A1 (en) * 1987-06-16 1988-12-29 Hoechst Ag ANTIMYCOTICALLY EFFECTIVE NAIL POLISH AND METHOD FOR THE PRODUCTION THEREOF
CH681427A5 (en) 1987-07-01 1993-03-31 Zambon Spa
US5181914A (en) * 1988-08-22 1993-01-26 Zook Gerald P Medicating device for nails and adjacent tissue
FR2646603B1 (en) 1989-05-03 1991-07-12 Oreal CLEANING COMPOSITION
US5219877A (en) * 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
DK0514435T3 (en) 1990-02-08 1993-11-29 Nattermann A & Cie Alcoholic aqueous gel-like phospholipid composition and its use
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
HU223343B1 (en) * 1991-05-20 2004-06-28 Novartis Ag. Compositions comprising allylamine derivatives, and process for their preparation
JPH0739325B2 (en) * 1991-06-24 1995-05-01 株式会社島津製作所 Antifungal agent for home
US5985860A (en) * 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
US5318960A (en) * 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
DE4337945A1 (en) * 1993-11-06 1995-05-11 Labtec Gmbh Plasters for the treatment of nail mycoses
US5514698A (en) * 1994-03-21 1996-05-07 Ortho Pharmaceutical Corporation Antifungal vaginal cream composition
US5652256A (en) * 1995-06-06 1997-07-29 Knowles; W. Roy Topical composition for fungal treatment
EP0866683A4 (en) * 1995-09-14 1999-01-07 Sorenson Pharmaceutical Inc Composition and method for treating diseased nails
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US20040039030A1 (en) * 1996-09-27 2004-02-26 Hoechst Akeengesellschaft Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
US5807957A (en) * 1996-12-23 1998-09-15 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
US5935577A (en) * 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
US6159977A (en) * 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
AU778343B2 (en) * 1999-02-05 2004-12-02 Mediquest Therapeutics, Inc. Antizyme modulators and their use
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
SE0000303D0 (en) * 2000-01-31 2000-01-31 Xylogen Ab Novel compounds
DE10011081A1 (en) * 2000-03-09 2001-09-13 Aventis Pharma Gmbh Lacquer formulation for treating and preventing onychomycosis, comprising combination of systemic and topical antimycotic agents in film-forming polymer base
US6485740B1 (en) * 2000-03-14 2002-11-26 Yutoku Pharmaceutical Ind., Co., Ltd. Transdermal methotrexate preparations
CA2423930C (en) 2000-10-27 2009-11-24 Leo Pharma A/S Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
HUP0303826A2 (en) * 2001-02-01 2004-03-01 Biogen, Inc. Methods for treating or preventing skin disorders using cd2-binding agents
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
JP4843169B2 (en) * 2001-02-27 2011-12-21 株式会社Adeka Disinfectant cleaning composition
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030091540A1 (en) * 2001-10-16 2003-05-15 Nawaz Ahmad Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
JP2004083439A (en) * 2002-08-23 2004-03-18 Ss Pharmaceut Co Ltd External antifungal preparation for nail
US6914079B2 (en) * 2002-09-23 2005-07-05 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US7135194B2 (en) * 2002-09-27 2006-11-14 Birnbaum Jay E Subunguicide, and method for treating onychomycosis
CA2513399A1 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications

Patent Citations (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
US4755534A (en) * 1979-08-22 1988-07-05 Sandoz Ltd. Propenylamines, pharmaceutical compositions containing them and their use as pharmaceuticals
US5132459A (en) * 1979-08-22 1992-07-21 Sandoz Ltd. Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US4567161A (en) * 1982-07-09 1986-01-28 A. Natterman & Cie Gmbh Liquid active ingredient concentrates for preparation of microemulsions
US5030625A (en) * 1984-11-22 1991-07-09 Sandoz Ltd. Anti-fungal homopropargylamine compounds
US4684661A (en) * 1984-11-22 1987-08-04 Sandoz Ltd. Anti-fungal homopropargylamines, compositions, and method of use therefor
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4788061A (en) * 1985-07-05 1988-11-29 Shore Ronald N Extended occlusive treatment of skin disorders
US4764381A (en) * 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US4751245A (en) * 1986-06-25 1988-06-14 E. R. Squibb & Sons, Inc. Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same
US5591774A (en) * 1986-12-23 1997-01-07 Yu; Ruey J. Method of treating wrinkles using malic acid
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US5045317A (en) * 1987-07-16 1991-09-03 The Regents Of The University Of California Enhancing the cutaneous penetration of pharmacologically active agents
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US4920112A (en) * 1988-04-18 1990-04-24 Merck & Co., Inc. Fungicidal compositions and method
US5231183A (en) * 1989-10-02 1993-07-27 Banyu Pharmaceutical Co., Ltd. Process for producing enyne derivatives
US5296612A (en) * 1989-10-02 1994-03-22 Banyu Pharmaceutical Co., Ltd. Process for producing enyne derivatives
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5741513A (en) * 1990-02-08 1998-04-21 A. Natterman & Cie. Gmbh Alcoholic aqueous gel-like phospholipid composition, its use and topical preparations containing it
US5385911A (en) * 1990-12-18 1995-01-31 Merrell Dow Pharmaceuticals Inc. Anti-herpes castanospermine esters
US5814305A (en) * 1991-03-08 1998-09-29 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US6455592B1 (en) * 1991-03-08 2002-09-24 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US6143793A (en) * 1991-03-08 2000-11-07 Novartis Ag Use of hydrophilic penetration agents in dermatological compositions for the treatment of onychomycoses, and corresponding compositions
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US5401742A (en) * 1993-05-11 1995-03-28 Japan, As Represented By Director General Of Agency Of Industrial Science And Technology Polymeric conjugate of methotrexate compound and pyran copolymer and method for the preparation thereof
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US6017920A (en) * 1994-05-06 2000-01-25 Toko Yakuhin Kogyo Kabushiki Kaisha Antifungal composition for external use being retentive in stratum corneum
US5693676A (en) * 1994-05-27 1997-12-02 Neptune Pharmaceutical Corporation Nitric oxide donor composition and method for treatment of anal disorders
US6042845A (en) * 1994-12-22 2000-03-28 Johnson & Johnson Consumer Products, Inc. Anti fungal treatment of nails
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
US5639740A (en) * 1995-03-10 1997-06-17 Crandall; Wilson Trafton Topical moisturizing composition and method
US6316428B1 (en) * 1995-03-10 2001-11-13 Wilson Trafton Crandall Topical moisturizing composition and method
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5985906A (en) * 1995-05-12 1999-11-16 Novartis Ag Antifungal composition
US5817875A (en) * 1995-09-20 1998-10-06 Karimian; Khashayar Methods for the manufacture of terbinafine
US6287601B1 (en) * 1996-11-19 2001-09-11 Meri Charmyne Russell Topical nitric oxide donor compositions
US6596287B2 (en) * 1997-05-27 2003-07-22 Semibiosys Genetics Inc. Products for topical applications comprising oil bodies
US6165975A (en) * 1997-06-23 2000-12-26 Queen's University At Kingston Microdose therapy
US6423683B1 (en) * 1997-06-23 2002-07-23 Queens University At Kingston Microdose therapy
US6610652B2 (en) * 1997-06-23 2003-08-26 Queen's University At Kingston Microdose therapy
US6172261B1 (en) * 1997-07-15 2001-01-09 Oridigm Corporation Polyamine analogues as therapeutic and diagnostic agents
US5993790A (en) * 1997-08-04 1999-11-30 Pedinol Pharmacal Inc. Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections
US6143794A (en) * 1998-04-17 2000-11-07 Bertek Pharmaceuticals, Inc. Topical formulations for the treatment of nail fungal diseases
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6632843B1 (en) * 2000-02-01 2003-10-14 Mark Friedman Treatment of bruxism
US20010056071A1 (en) * 2000-03-24 2001-12-27 Pelliccia Maria Teresa Use of resveratrol for the treatment of exfoliative eczema, acne and psoriasis
US6380236B2 (en) * 2000-04-12 2002-04-30 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US20010049386A1 (en) * 2000-04-12 2001-12-06 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US6281239B1 (en) * 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
US6538017B2 (en) * 2001-03-09 2003-03-25 Ortho-Mcneil Pharmaceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
US20040101538A1 (en) * 2001-03-30 2004-05-27 Catherine Larnier Topical composition
US20040197280A1 (en) * 2001-10-22 2004-10-07 Repka Michael A. Delivery of medicaments to the nail
US6673842B2 (en) * 2002-03-20 2004-01-06 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US20030181525A1 (en) * 2002-03-20 2003-09-25 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US20030181526A1 (en) * 2002-03-20 2003-09-25 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US6743417B2 (en) * 2002-04-22 2004-06-01 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis with urea and an antioxidant
US20040146470A1 (en) * 2002-04-22 2004-07-29 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis with urea and an antioxidant
US20030235541A1 (en) * 2002-06-21 2003-12-25 Maibach Howard I. Topical administration of basic antifungal compositions to treat fungal infections of the nails
US6846837B2 (en) * 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US20040096410A1 (en) * 2002-07-29 2004-05-20 Maley Joseph C. Methods and compositions for treatment of dermal conditions
US20050074414A1 (en) * 2002-10-25 2005-04-07 Foamix Ltd. Penetrating pharmaceutical foam
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510855B2 (en) 2018-09-27 2022-11-29 Dermaliq Therapeutics, Inc. Topical sunscreen formulation

Also Published As

Publication number Publication date
US20060110342A1 (en) 2006-05-25
AU2005294216B2 (en) 2010-06-24
US7776349B2 (en) 2010-08-17
BRPI0512583B8 (en) 2021-05-25
US20060078580A1 (en) 2006-04-13
BRPI0512583B1 (en) 2018-12-26
WO2006042059A1 (en) 2006-04-20
BRPI0512583A (en) 2008-03-25
CA2567575C (en) 2009-01-20
AU2005294216C1 (en) 2011-02-24
EP1796632A4 (en) 2009-03-11
JP2008515911A (en) 2008-05-15
AU2005294216A1 (en) 2006-04-20
KR20070072482A (en) 2007-07-04
EP1796632A1 (en) 2007-06-20
CA2567575A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
US7776349B2 (en) Organo-gel formulations for therapeutic applications
US7740875B2 (en) Organo-gel formulations for therapeutic applications
RU2429815C2 (en) Anhydrous polyphase gel system
US10821075B1 (en) Compositions for topical application of a medicaments onto a mammalian body surface
ES2318233T3 (en) IMPROVEMENT SYSTEMS OF PENETRATION AND IRRITATION REDUCERS THAT INCLUDE TESTOSTERONE.
US5639740A (en) Topical moisturizing composition and method
US7033998B2 (en) Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
JP2009519940A (en) Compositions and methods for treating dermatological conditions
US5652256A (en) Topical composition for fungal treatment
US6894078B2 (en) Alcohol based topical anesthetic formulation and method
US20110236503A1 (en) Topical Skincare Composition
Vanić Phospholipid vesicles for enhanced drug delivery in dermatology
EP1968541A2 (en) Compositions and methods for dermal delivery of drugs
Kaur et al. Topical gels: a review
RU2238092C2 (en) Aqueous medicinal composition for treatment of skin disease
Sharma et al. EMULGEL: A TOPICAL DRUG DELIVERY
MXPA05010939A (en) Alcohol-free transdermal analgesic composition
AU2012261730A1 (en) Anhydrous multiphase gel system

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION